International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology

@article{Neubig2003InternationalUO,
  title={International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology},
  author={Richard R. Neubig and Michael Spedding and Terry Kenakin and Arthur Christopoulos},
  journal={Pharmacological Reviews},
  year={2003},
  volume={55},
  pages={597 - 606}
}
The recommendations that follow have been updated from the proposals of a Technical Subcommittee set up by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, and Shankley NP (1995) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47:255–266). 

Tables from this paper

International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands
TLDR
An overview of allostery as applied to receptor families and approaches for detecting and validating allosteric interactions is presented and recommendations for the nomenclature ofAllosteric ligands and their properties are given.
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
TLDR
The International Union of Basic and Clinical Pharmacology/British Pharmacological Society (IUPHAR/BPS) Guide to PHARMACOLOGY is a new open access resource providing pharmacological, chemical, genetic, functional and pathophysiological data on the targets of approved and experimental drugs.
Drug-Target Association Kinetics in Drug Discovery.
The fall and rise of pharmacology--(re-)defining the discipline?
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
TLDR
This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015, and introduces the newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org).
Overview of Drug Discovery and Development
This overview unit describes the core activities involved in the drug discovery and development process, from target identification ‐ including preclinical biology, medicinal and process chemistry ‐
Principles of pharmacodynamics and their applications in veterinary pharmacology.
TLDR
This review introduces and summarizes the principles of PDs and illustrates them with examples drawn from both basic and veterinary pharmacology.
The Hill equation and the origin of quantitative pharmacology
TLDR
The Hill equation has remained an important tool for physiological and pharmacological investigations including drug discovery, moreover it serves as a theoretical basis for the development of new pharmacological models.
Link between a high k on for drug binding and a fast clinical action: to be or not to be?
TLDR
The presented simulations tally with a positive link between a drug's effective/observed association rate and the swiftness of its clinical action, and show that the k on-concept should not be confounded with the effective association process.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
International Union of Pharmacology. XXXI. Recommendations for the Nomenclature of Multimeric G Protein-Coupled Receptors
A receptor is defined by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) as a protein, or a complex of proteins, which recognizes
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
This issue of Pharmacological Reviews includes a new venture in the collaboration between the International Union of Pharmacology (IUPHAR) and the American Society for Pharmacology and Experimental
pAx and competitive drug antagonism.
  • H. Schild
  • Biology
    British journal of pharmacology and chemotherapy
  • 1949
TLDR
Guarino and Bovet evolve a new formula for the quantitative relations of antagonistic drugs whereby pA would be dependent on the concentration of active drug in competitive antagonism.
A Pharmacologic Analysis of Drug-Receptor Interaction
Drug receptor/theory seven transmembrane receptor behaviour human recombinant receptor systems stimulus-response mechanisms drug response mechanisms diffusion and drug concentration in receptor
A MODIFICATION OF RECEPTOR THEORY
TLDR
An attempt has been made to determine the relation between log concentration and effect for acetylcholine and the frog rectus abdominis after blocking the cholinesterase activity of isolated rabbit auricles.
Operational models of pharmacological agonism
  • J. Black, P. Leff
  • Biology
    Proceedings of the Royal Society of London. Series B. Biological Sciences
  • 1983
TLDR
An alternative model is proposed, representing the cognitive and transducer functions of a receptor, that describes agonist action with one fewer parameter than the traditional model, and provides a chemical definition of intrinsic efficacy making this parameter experimentally accessible in principle.
pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM
  • H. Schild
  • Biology
    British journal of pharmacology and chemotherapy
  • 1947
TLDR
This is the first of a set of three papers in the Journal that were to transform the study of drug antagonism and Schild proposed and validated a new measure of antagonist action, pA, and showed how pAx measurements could provide a reproducible and statistically satisfactory index of the effectiveness of an antagonist action.
Analysis of competitive agonist-antagonist interactions by nonlinear regression.
SOME QUANTITATIVE USES OF DRUG ANTAGONISTS
TLDR
Various applications of pAx measurements are discussed based on the hypothesis that drugs and drug antagonists compete for receptors according to the mass law, and a new measure, pAh, is introduced to express the activity of unsurmountable antagonists.
The ligand paradox between affinity and efficacy: can you be there and not make a difference?
...
...